A comprehensive overview of the disease behind the 2026 MV Hondius outbreak. Source-cited content drawn from our verified knowledge base.
Hantavirus is a family of negative-sense RNA viruses (family Hantaviridae, order Bunyavirales) carried by rodents. Two clinical syndromes can result from human infection:
The 2026 MV Hondius outbreak involves Andes orthohantavirus (ANDV), a New World hantavirus endemic to southern Argentina and Chile, first isolated in 1995 in Chile. ANDV is the only hantavirus species with documented person-to-person transmission.
Inhalation of aerosolized rodent urine, feces, or saliva in enclosed spaces — barns, cabins, abandoned buildings, landfills. The reservoir host for ANDV is the long-tailed pygmy rice rat (Oligoryzomys longicaudatus), endemic to southern Argentina and Chile. Rodents are asymptomatic carriers. Aerosolized virus can survive up to 2 weeks in cool, dark conditions but is rapidly inactivated by sunlight, bleach, and 70% ethanol.
Person-to-person transmission requires close and prolonged contact: shared enclosed living spaces, bedside care, or sustained face-to-face exposure to respiratory secretions. Casual or brief contact is insufficient. A KLM flight attendant had 45 minutes of direct contact with a symptomatic MV Hondius patient (MVH-002) on flight KL592 and tested negative — WHO confirmed the brief encounter did not result in transmission.
Person-to-person transmission was first proven in the 1996 El Bolsón outbreak, when three physicians developed HPS 27–28 days after treating the index patient. Peak infectiousness occurs at symptom onset during the prodromal phase, when viral load peaks and patients may appear to have only mild flu.
Incubation ranges 9 to 40 days (median ~18 days). The disease progresses in three phases:
Higher severity is associated with age 60+, pre-existing hypertension, diabetes, smoking history, higher viral load at presentation, and concurrent liver injury.
RT-PCR on serum can detect ANDV RNA 5–15 days before symptom onset or antibody detection — critical for early diagnosis in exposed contacts. IgM and IgG antibodies appear by approximately day 10 after symptom onset; IgM persists for months, IgG often for years. Diagnosis combines clinical presentation, exposure history, and laboratory confirmation.
No specific antiviral works against hantavirus. Ribavirin showed no significant mortality reduction in meta-analysis (RR 0.99, 95% CI 0.60-1.61) and is not recommended.
Treatment is supportive: intensive hemodynamic monitoring, aggressive fluid management (avoiding overload, which worsens pulmonary edema), mechanical ventilation when needed.
ECMO (extracorporeal membrane oxygenation) is the most effective intervention for severe HCPS. ECMO acts as a heart-lung bypass while the body clears the infection and achieves up to 80% survival when started before cardiovascular collapse. Without ECMO, case fatality is 30–50%.
No licensed hantavirus vaccine exists anywhere in the world. The most advanced candidate is a DNA vaccine developed at the US Army Medical Research Institute of Infectious Diseases (USAMRIID), which has completed Phase 1 trials. Moderna has a preclinical mRNA collaboration with USAMRIID and Korea University but it is years from human availability. ANDV-specific candidates are in early-phase trials in Argentina and Chile.
The molecular basis for ANDV's person-to-person transmission remains unknown. Compared to Sin Nombre virus (SNV), ANDV produces higher mucosal viral burdens, is uniformly lethal in Syrian hamster models (SNV is not), and more effectively interferes with interferon signaling. The combination is what makes ANDV the only hantavirus with documented person-to-person transmission.
The reproduction number (R0) for ANDV person-to-person transmission is estimated below 1 (around 0.7 for the MV Hondius cluster) — meaning each case infects fewer than one other person on average. Without sustained R0 above 1, an outbreak burns out rather than expands. WHO assesses global risk as LOW. CDC classifies the outbreak as Level 3 emergency activation (the lowest tier).
Both prior ANDV outbreaks (1996 El Bolsón, 2018 Epuyén) self-limited. The MV Hondius cluster is being managed with the same posture: surveillance, contact tracing, and isolation rather than mass quarantine. See the FAQ below for common questions about pandemic risk.
Frequently asked questions about hantavirus and the MV Hondius outbreak. Each answer is drawn from the verified facts in our knowledge base and current data on the live tracker.
Hantavirus is a family of viruses carried by rodents that can cause serious illness in humans. The strain in the 2026 MV Hondius outbreak is Andes orthohantavirus (ANDV) — a New World hantavirus endemic to southern Argentina and Chile, and the only hantavirus species known to spread between humans (in rare circumstances of close, prolonged contact). ANDV causes Hantavirus Cardiopulmonary Syndrome (HCPS), which affects the lungs and heart.
The primary route is inhalation of aerosolized rodent urine, feces, or saliva in enclosed spaces — barns, cabins, abandoned buildings, landfills. The reservoir host for ANDV is the long-tailed pygmy rice rat (Oligoryzomys longicaudatus). For ANDV specifically, person-to-person spread is also documented, but it requires close and prolonged contact: shared living spaces, bedside care of severely symptomatic patients, or sustained face-to-face interaction. Casual or brief contact is not sufficient.
No, hantavirus is not airborne in the way measles or COVID-19 are. It cannot float through ventilation systems or infect people across a room from a single cough. Transmission requires either direct exposure to fresh rodent excreta in enclosed spaces, or close and prolonged contact with an infected person. A KLM flight attendant had 45 minutes of direct contact with a symptomatic MV Hondius patient (MVH-002) on flight KL592 and tested negative — WHO confirmed the brief encounter did not result in transmission.
Only Andes virus (ANDV) — the strain in the MV Hondius outbreak — has documented person-to-person transmission, and only under specific conditions: close and prolonged contact with a symptomatic patient. Other hantaviruses (Sin Nombre, Hantaan, Seoul, Puumala, Dobrava) have no documented human-to-human spread. Person-to-person transmission was first proven in the 1996 El Bolsón outbreak in Argentina.
A cluster of hantavirus infections aboard the Dutch-flagged cruise ship MV Hondius, identified in April 2026. The likely index couple was exposed during a birdwatching excursion at Ushuaia landfill in Argentina before boarding the ship on April 1. The cluster spread among passengers and crew during the voyage. As of early May 2026 it includes confirmed and suspected cases in the Netherlands, Germany, Switzerland, the UK, Spain, Saint Helena, and the United States, with three deaths reported. The ship arrived in Tenerife on May 10 for managed disembarkation.
The case fatality rate for ANDV historically ranges from 30% to 50% — among the deadliest infectious diseases when contracted. The MV Hondius cluster currently shows 3 deaths from approximately 9 cases (about 33%). Death typically results from massive pulmonary edema and cardiogenic shock within 24–48 hours of severe respiratory symptoms developing. Survival is highest with early ECMO (extracorporeal membrane oxygenation) — up to 80% survival when started before cardiovascular collapse.
No licensed hantavirus vaccine exists anywhere in the world. The most advanced candidate is a DNA vaccine developed at the US Army Medical Research Institute of Infectious Diseases (USAMRIID), which has completed Phase 1 trials. Moderna has a preclinical mRNA collaboration with USAMRIID and Korea University but it is years from human availability. ANDV-specific candidates are in early-phase trials in Argentina and Chile.
No specific antiviral works against hantavirus. Ribavirin showed no significant mortality reduction in meta-analysis and is not recommended. Treatment is purely supportive — intensive hemodynamic monitoring, careful fluid management, mechanical ventilation when needed. The most effective intervention for severe HCPS is ECMO (extracorporeal membrane oxygenation), which acts as a heart-lung bypass while the body clears the infection. ECMO achieves about 80% survival when started early, before full cardiovascular collapse.
Incubation ranges from 9 to 40 days, with a median of about 18 days. This long and variable window is why public-health authorities (WHO, ECDC) recommend a 42-day surveillance period for contacts of confirmed cases. The MV Hondius outbreak response plans use the 42-day window for monitoring exposed passengers and crew.
Hantavirus illness progresses in three phases. Phase 1 (prodromal, 1–5 days): fever, chills, severe muscle aches, headache, and gastrointestinal symptoms — clinically indistinguishable from flu. Phase 2 (cardiopulmonary): rapid onset of shortness of breath, fluid in the lungs, low blood pressure, and risk of cardiogenic shock. Phase 3 (convalescent or terminal). The transition from Phase 1 to Phase 2 can be rapid — within hours — making early recognition critical.
Public-health authorities currently rate this as low likelihood. The reproduction number (R0) for ANDV person-to-person transmission is estimated below 1 (around 0.7 for the MV Hondius cluster), meaning each case infects fewer than one other person on average — outbreaks burn out rather than expand. WHO assesses global risk as LOW. CDC classifies the outbreak as Level 3 emergency activation (the lowest tier). Past ANDV outbreaks (1996 El Bolsón with 18 cases, 2018 Epuyén with 36 cases) both self-limited without sustained spread.
Two notable ANDV outbreaks predating MV Hondius. (1) El Bolsón, Argentina, 1996: 18 cases — the first outbreak to prove human-to-human transmission, with three physicians infected by their index patient. (2) Epuyén, Argentina, 2018–2019: 36 cases and 11 deaths, published in NEJM, demonstrating superspreader dynamics — Patient #1 infected 5 people in 90 minutes at a birthday party. Both outbreaks self-limited without sustained spread, consistent with R0 below 1.
Risk factors for severe HCPS include age 60+, pre-existing hypertension, diabetes, smoking history, higher viral load at presentation, and concurrent liver injury. American Indian women aged 40–64 have the highest demographic risk for hantavirus exposure historically. For the MV Hondius cluster, the index cases were a Dutch couple in their late 60s.
For the live outbreak picture see the main dashboard. For the verified-fact knowledge base see /facts.
Sourced from WHO, CDC, ECDC, peer-reviewed publications (NEJM, Lancet, JAMA), and primary government statements. Each fact in the underlying knowledge base carries its own source attribution.